Patents by Inventor Michael K. Ahlijanian

Michael K. Ahlijanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 11827695
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: November 28, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 11142570
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: October 12, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20210221878
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Application
    Filed: January 19, 2021
    Publication date: July 22, 2021
    Inventors: Michael K. AHLIJANIAN, Jere Ernest MEREDITH, Jr., Nino DEVIDZE, John David GRAEF, Edward L. HALK
  • ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20200231661
    Abstract: Disclosed herein are anti-?-synuclein antibodies which preferentially bind to oligomeric ?-synuclein over monomeric ?-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
    Type: Application
    Filed: February 16, 2018
    Publication date: July 23, 2020
    Inventors: Michael K. AHLIJANIAN, Jere Ernest MEREDITH, Jr., Nino DEVIDZE, John David GRAEF, Edward L. HALK
  • Imidazole derivatives
    Patent number: 7078529
    Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: July 18, 2006
    Assignee: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Patricia A. Seymour, Michael K. Ahlijanian, Anabella Villalobos, Lit-Fui Lau
  • Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
    Patent number: 6936638
    Abstract: Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: August 30, 2005
    Assignees: Migenix Corp., Pfizer Inc.
    Inventors: Soumitra S. Ghosh, Yazhong Pei, Xiao-Qing Tang, Spiros J. Liras, Michael K. Ahlijanian
  • Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
    Publication number: 20040192740
    Abstract: Compounds which have utility in the treatment of conditions associated with altered mitochondrial function.
    Type: Application
    Filed: December 19, 2003
    Publication date: September 30, 2004
    Applicants: MitoKor, Inc., Pfizer Inc.
    Inventors: Soumitra S. Ghosh, Yazhong Pei, Xiao-Qing Tang, Spiros Liras, Michael K. Ahlijanian
  • Imidazole derivatives
    Publication number: 20040192750
    Abstract: The invention provides compounds of formula 1 1
    Type: Application
    Filed: April 5, 2004
    Publication date: September 30, 2004
    Applicant: Pfizer Inc
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Patricia A. Seymour, Michael K. Ahlijanian, Anabella Villalobos, Lit-Fui Lau
  • Imidazole derivatives
    Patent number: 6756385
    Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Michael K. Ahlijanian, Annabella Villalobos, Lit-Fui Lau, Patricia A. Seymour
  • Transgenic mice expressing human p25
    Patent number: 6693226
    Abstract: The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 (activator of the protein kinase cdk 5) polypeptide. The two neuropathological lesions associated with Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles (NFTs), composed predominantly of amyloid &bgr; peptides and hyperphosphorylated tau, respectvely. While animal models for plaque formation exist, there is no animal model that recapitulates the formation of NFTs. This invention provides transgenic mice that overexpress human p25, an activator of cdk5, resulting in tau that is hyperphosphorylated at AD-relevant epitopes. Deposition of tau is detected in the amygdala, thalamus and cortex. Increased phosphorylated neurofilament, silver-positive neurons and neuronal death are also observed in these regions. We conclude that the overexpression of p25, an activator of cdk5, is sufficient to produce hyperphosphorylation of tau and neuronal death.
    Type: Grant
    Filed: February 2, 2000
    Date of Patent: February 17, 2004
    Assignee: Pfizer Inc
    Inventors: John D. McNeish, Michael K. Ahlijanian
  • Transgenic animals expressing human p25
    Publication number: 20030145343
    Abstract: The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 (activator of the protein kinase cdk 5) polypeptide.
    Type: Application
    Filed: February 11, 2003
    Publication date: July 31, 2003
    Applicant: Pfizer Inc.
    Inventors: John D. McNeish, Michael K. Ahlijanian
  • Imidazole derivatives
    Publication number: 20020119963
    Abstract: The invention provides compounds of formula 1 1
    Type: Application
    Filed: July 31, 2001
    Publication date: August 29, 2002
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Michael K. Ahlijanian, Anabella Villalobos, Lit-Fui Lau, Patricia A. Seymour